Trial tests stronger drug combo to keep blood cancer at bay
NCT ID NCT02389517
Summary
This study tested if adding two more drugs (ixazomib and dexamethasone) to a standard maintenance drug (lenalidomide) was better at controlling residual multiple myeloma after a stem cell transplant. It involved 42 patients who still had small amounts of cancer detectable after their initial treatment. The main goal was to see which treatment plan could better eliminate these last traces of cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.